Trevena

company

About

Trevena is a clinical stage biopharmaceutical company discovering and developing G-protein coupled receptors (GPCR) biased ligands.

  • 51 - 100

Details

Last Funding Type
Grant
Last Funding Money Raised
$7.65M
Industries
Biopharma,Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2007
Number Of Employee
51 - 100
Operating Status
Active

Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines.

They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.

G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$7.65M
Trevena has raised a total of $7.65M in funding over 2 rounds. Their latest funding was raised on Nov 3, 2009 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 3, 2009 Grant $7.65M 1 National Institutes of Health (NIH) Detail

Investments

Number of Investments
Number of Lead Investments
1
0
Trevena has made 1 investments. Their most recent investment was on Nov 30, 2022, when Suraasa raised ₹96M.
Date Company Name
Round Money Raised Industry Lead Investor
Nov 30, 2022 Suraasa
Seed ₹96M Apps

Investors

Number of Lead Investors
Number of Investors
1
1
Trevena is funded by 1 investors. National Institutes of Health (NIH) are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health (NIH) Yes Grant